Abstract: The present invention discloses a novel compound of Formula 1, and an organic electroluminescent device using the same. In Formula 1, X and Y independently represents an aromatic or a hetero aromatic hydrocarbon having a carbon number of from 5 to 10. Ar1 to Ar7 each independently represents an unsubstituted or substituted aromatic hydrocarbon having a carbon number of from 4 to C12, or an unsubstituted or substituted condensed polycyclic aromatic hydrocarbon having a carbon number of from 4 to 12; Ar1 to Ar7 can form an annulated or fused aromatic ring system with the adjacent aromatic hydrocarbons. When the compound of Formula I is used in the device, high luminous efficiency, longer lifetime and low driving voltage can be achieved.
Abstract: The present invention relates to a novel amide derivative. More specifically, the present invention provides a medicinal agent useful as a prophylactic or therapeutic agent for diseases, which relies on the production of cytokines from T cells, and which comprises an amide derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or the pharmacologically acceptable salt as an active ingredient. Provided is an amide derivative represented by general formula (I) [wherein each symbol is as defined in the description] or a pharmacologically acceptable salt thereof, or a solvate of the derivative or the pharmacologically acceptable salt.
Abstract: This invention relates to the discovery of novel forms of Compound 1, including solvates, hydrates, and other crystalline forms. These novel forms of Compound 1 may impart advantages in pharmaceutical formulations incorporating them, including improved stability and bioavailability.
Type:
Grant
Filed:
September 23, 2013
Date of Patent:
October 6, 2015
Assignee:
Curis, Inc.
Inventors:
Noel Hamill, James Moody, Sébastien Chabaud, Arnaud Hamel
Abstract: The present invention relates to novel fluorinated piperidine derivatives having antagonistic activity at the 5-HT2B receptor, pharmaceutical compositions comprising these compounds and their use as a medicine.
Type:
Grant
Filed:
March 4, 2014
Date of Patent:
September 22, 2015
Assignee:
Janssen Pharmaceutica, NV
Inventors:
Johannes Wilhelmus John F. Thuring, Luc August Laurentius Ver Donck
Abstract: Disclosed in the present invention are polycyclic derivatives as represented by general formula (I), the preparation method thereof, pharmaceutical compositions containing the derivatives and uses thereof as therapeutic agents, especially the GPR40 agonist and in preparation of drugs for treating diseases such as diabetes and metabolic disorders, etc., wherein each substituent in the general formula (I) has the same definition as in the description.
Abstract: A biguanide derivative compound with N4-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK and inhibition of cancer cell proliferation in a low dose, compared with conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.
Type:
Grant
Filed:
January 6, 2011
Date of Patent:
September 15, 2015
Assignee:
Hanall Biopharma Co., Ltd.
Inventors:
Sung Wuk Kim, Sung Soo Jun, Chang Hee Min, Se Hwan Park, Yong Eun Kim, Duck Kim, Ji Sun Lee, Ju Hoon Oh
Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water soluble oligomer.
Type:
Grant
Filed:
April 30, 2014
Date of Patent:
September 15, 2015
Assignee:
Nektar Therapeutics
Inventors:
Zhongxu Ren, Bo-Liang Deng, Jennifer Riggs-Sauthier, Micah Harvey
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.
Type:
Grant
Filed:
November 15, 2013
Date of Patent:
September 15, 2015
Assignee:
Bristol-Myers Squibb Company
Inventors:
Bruce A. Ellsworth, Jun Shi, William R. Ewing, Elizabeth A. Jurica, Andres S. Hernandez, Ximao Wu
Abstract: The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, and R4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
Type:
Grant
Filed:
January 18, 2012
Date of Patent:
September 15, 2015
Assignee:
Actelion Pharmaceuticals Ltd.
Inventors:
Martin Bolli, Cyrille Lescop, Boris Mathys, Keith Morrison, Claus Mueller, Oliver Nayler, Beat Steiner
Abstract: Pharmaceutical compositions of the invention comprise alkylated imino sugars derivatives having a disease-modifying action in the treatment of diseases associated with glucosidase activity that include Viral hemorrhagic fevers, and any other diseases involving glucosidase activity.
Type:
Grant
Filed:
March 27, 2013
Date of Patent:
September 8, 2015
Assignees:
Baruch S. Blumberg Institute, Drexel University
Inventors:
Yanming Du, Xiaodong Xu, Hong Ye, Jinhong Chang, Timothy M. Block
Abstract: The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range.
Type:
Grant
Filed:
November 1, 2013
Date of Patent:
September 1, 2015
Assignee:
AICURIS GMBH & CO KG
Inventors:
Wilfried Schwab, Alexander Birkmann, Kerstin Paulus, Kurt Vogtli, Dieter Haag, Stephan Maas, Kristian Ruepp
Abstract: The invention provides an indazole compound of formula (I) which is capable of inhibiting HSP90 and shows a cytostatic effect on cancer cells:
Abstract: The use of compounds in the treatment of skin disorders is described. In particular, use of a compound of formula (I): or one of its pharmaceutically acceptable salts, solvates or hydrates in the preparation of a medicament to treat skin pathologies is described.
Type:
Grant
Filed:
December 22, 2010
Date of Patent:
September 1, 2015
Assignee:
GALDERMA RESEARCH & DEVELOPMENT
Inventors:
Cédric Poinsard, Patrice Lucien Maurice Collette, Isabelle Marie Joëlle Martine Collette, Pascale Mauvais, Jean-Michel Linget, Sandrine Rethore
Abstract: The present invention relates to substituted fused tricyclic compounds of formula (I) or (Ia), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by JAK activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by JAK activity.
Abstract: The present application is directed to an efficient conversion of C-14 hydroxylated morphine alkaloids to various morphine analogs, such as naltrexone, naloxone and nalbuphone. One feature of this process is an intramolecular functional group transfer from the C-14 hydroxyl to the N-17 nitrogen atom following a palladium-catalyzed N-demethylation.
Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing moderate to severe pain, may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of muscle pain, spasticity, neuropathic pain, fibromyalgia, post-operative pain, muscle spasticity, headache, chronic pain, sub-chronic pain and local pain.